Lessons Learned From the CAPTIVATE Trial of Ibrutinib Plus Venetoclax in CLL

H&O Could you describe the design of the CAPTIVATE trial? SO CAPTIVATE is a phase 2 trial in patients with previously untreated chronic lymphocytic leukemia (CLL) […]

Should Venetoclax Be Used With or Without Anti-CD20 Therapy for CLL?

H&O Which patients with chronic lymphocytic leukemia (CLL) are eligible for treatment with venetoclax? RF Nearly all patients with CLL are eligible for treatment with venetoclax […]

Early Intervention in Asymptomatic Chronic Lymphocytic Leukemia

Abstract: Of the estimated 21,000 patients who will receive a new diagnosis of chronic lymphocytic leukemia (CLL) this year in the United States, approximately 80% will […]

CLL In Focus

CLL Linked to Elevated Risk for Second Cancers Even With BTK Inhibition Patients with chronic lymphocytic leukemia (CLL) are at increased risk for second cancers even […]

Highlights in Chronic Lymphocytic Leukemia From the 2020 American Society of Clinical Oncology Annual Meeting

May 29-31, 2020 • Virtual Venetoclax/Obinutuzumab Continues to Demonstrate Superior Efficacy Long-term results from the CLL14 trial continue to show that fixed-duration venetoclax/obinutuzumab (VenG) continues […]

CLL in Focus

Watch and Wait Remains Best Approach for High-Risk Binet Stage A Chronic Lymphocytic Leukemia The current standard of care for patients with Binet stage A chronic […]

CLL In Focus

Complete Response Linked to Progression-Free Survival in Chronic Lymphocytic Leukemia Progression-free survival (PFS) is longer in patients with chronic lymphocytic leukemia (CLL) who have a complete […]